Guerbet SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Guerbet SA's Lipiodol approved for reimbursement in Japan when used for Transcatheter Arterial Chemo-embolization
Guerbet SA:Says its Guerbet Japan announced that the company's Lipiodol drug is approved for National Health Insurance reimbursement for Transcatheter Arterial Chemo-Embolization (TACE) for hepatocarcinoma cellular when used with Pfizer Japan Inc.'s Farmorubicin drug.Says this approval for insurance reimbursement follows Ministry of Health, Labor and Welfare (MHLW) approval of a new Lipiodol indication for adjustment of drugs and medical devices received by the company on Sep. 13, 2013.
Latest Developments for Guerbet SA
- Guerbet SA announces FDA approves Lipiodol (Ethiodized Oil) injection for imaging of tumors in adults
- Guerbet SA proposes FY 2013 dividend and issues FY 2014 financial guidance
- Guerbet launches CE-marked FlowSens solution on global markets
- Guerbet SA receives FDA approval for new manufacturing plant for Lipiodol injection
Latest Key Developments in Pharmaceuticals
- Share this
- Digg this